Fosun's merger and acquisition will begin! Split medical equipment company to Hong Kong for financing

With the approval of Hong Kong stock exchange for Fosun Pharmaceutical's split of sisram, it means that its strategy to build a financing platform for medical devices has officially spread, followed by Fosun Pharmaceutical's global M & A and integration of medical devices with the help of the platform On June 6, Fosun Pharmaceutical and Fosun International released a joint announcement Fosun Pharmaceutical and Fosun international, its controlling shareholder, have made a joint application to the stock exchange of Hong Kong in accordance with the listing rules, seeking relevant proposals to spin off sisram, a non wholly owned subsidiary of Fosun Pharmaceutical, and obtained independent listing approval on the main board of the stock exchange The stock exchange of Hong Kong has confirmed that Fosun Pharmaceutical and Fosun international can make a proposal for spin off And listing Sisram is a subsidiary of Fosun Pharma, which was established in Israel in 2013 On May 27 of that year, Fosun Pharma acquired Alma, an Israeli medical beauty equipment company, through sisram In the acquisition of Alma, Fosun Pharmaceutical once said that Alma would be listed separately in 54 months since the acquisition, that is, at the end of 2017 Fosun Pharmaceutical system is mainly divided into four parts: pharmaceutical industry, pharmaceutical business, medical services, medical devices and medical diagnosis Among them, the main platform of Fosun Pharmaceutical is the pharmaceutical industry, while the pharmaceutical business mainly focuses on Sinopharm holdings Now, if sisram is separated and listed separately, it will become the medical device platform of Fosun system 1 Open the M & a mode When the listing of sisram is completed, according to the practice of Fosun and the planning of the platform, it will further increase the M & A in the field of medical devices After years of layout, Fosun Pharmaceutical has completed the creation of medical device R & D, production, sales platform and medical device agent platform In its 2016 financial report, Fosun Pharmaceutical described the medical device business, mainly including dental products (own products and agent business), blood transfusion and surgical consumables, medical beauty devices and surgical products   Dentistry is an early field of instruments entered by Fosun pharma Fosun dental business department established in 2002 is a professional dental business enterprise under Fosun pharma It mainly acts as the agent of Germany bego, Netherlands vertx, Denmark 3shape (oral scanning Series), USA stratsys and other brands With this perfect business network and clinical technical resources, Fosun dental business department is located in the domestic market Forefront At the same time of agency, Fosun Pharmaceutical also actively promotes the dental business from the import product agency to the R & D and manufacturing of dental materials and equipment In addition to the agency in the field of Dentistry, Fosun Pharmaceutical also has a medical equipment agency platform - mutually beneficial medical treatment between the United States and China, which is mainly engaged in the sales agency of high-end imported medical equipment, the research and development, manufacturing, sales and marketing of blood transfusion equipment and surgical consumables In addition, on the basis of agency, Fosun Pharmaceutical integrates the production and sales of medical device consumables and business in China and the agency sales business of high-end medical devices based on the platform of mutual benefit between the United States and China It is worth mentioning that in May this year, Hexia medical service platform of Fosun Pharmaceutical announced that its parent company, US China mutual benefit, has reached an agreement with Fosun Pharmaceutical to transfer its 30% equity of us China mutual benefit medical to nenyue Co., Ltd., a wholly-owned holding company of Fosun Pharmaceutical This adjustment is just for the listing of sisram On the other hand, Alma, the world's largest medical laser equipment company, is based on its US $221 million acquisition What's more, this acquisition is an important step for Fosun Pharmaceutical to develop into medical device manufacturing and R & D Alma has a mature market system and market leading position Its business covers 60 countries and regions such as the United States and Germany In 2016, Alma achieved a revenue of 780 million yuan In addition to the business already carried out, Fosun also purchased 80% of goldcup at the price of 90 million US dollars (about 619 million yuan) at the beginning of this year As a result, Fosun Pharmaceutical won the European respiratory equipment brand breas and entered the respiratory market In June 2016, Fosun also completed the c-round investment in spirosure, a silicon valley respiratory disease testing company For the development of medical device platform, Fosun Pharmaceutical said in its 2016 annual report that in 2017, it will increase investment and continue to strengthen the R & D, manufacturing and sales of medical devices Alma lasers, a subsidiary of sisram group It will further accelerate the development and sales of medical treatment devices, actively explore the collaboration with other business sectors and business model innovation, so as to realize the extension of device supply to service At the same time, the group will continue to give full play to the advantages of internationalization, take the existing overseas enterprises as the platform, vigorously expand the cooperation business with overseas enterprises on the basis of positive integration, seek investment opportunities for domestic and foreign excellent equipment enterprises and the introduction of high-end medical equipment, and take precision medicine as the goal, so as to achieve the scale growth of medical equipment business Will medical diagnosis be split? When Fosun Pharmaceutical describes its business, it often puts medical devices and medical diagnosis together, but will sisram include this business? Fosun Pharmaceutical said in the announcement that the edited application version of the prospectus of sisram is expected to be available for browsing and downloading on the website of Hong Kong stock exchange from June 6, 2017, but Facebook has not yet seen the document on the website of the stock exchange As early as at the end of 2015, when the board of directors held a meeting, it was proposed to propose to the general meeting of shareholders to approve the initial public offering of H shares by the holding subsidiary, anergy biotechnology, and to be listed on the stock exchange of Hong Kong, but there was no substantial progress after that Therefore, it is possible for the outside world to separate the medical diagnosis business from the market Fosun Pharmaceutical is one of the earliest domestic enterprises involved in in vitro diagnosis business It has a comprehensive layout in biochemical diagnosis, immunodiagnosis, molecular diagnosis and other fields Its related enterprises include Fosun Long March, sub energy biology, Shanghai Xingyao and Shanghai Xingbai, etc Among them, Fosun Long March is the investment management platform of the company's medical diagnosis business department Founded in 1989, Shanghai Fosun Changzheng Medical Science Co., Ltd is a municipal high-tech enterprise integrating product R & D, production and sales of in vitro diagnosis, laboratory reagents and diagnostic equipment At present, it is a wholly-owned holding enterprise of Fosun Pharmaceutical Long march has formed a series of products such as clinical chemical analysis reagent, enzyme-linked immunoassay reagent, immunoturbidimetric analysis reagent, blood gas and electrolyte analyzer supporting reagent, becoming one of the most influential in vitro diagnostic reagent brands in China, with sales and after-sales network all over the country The company was founded in 2001 and became a 50.1% holding subsidiary of Fosun Changzheng in 2010 Relying on independent innovation, sub energy biology has successfully developed a practical gene chip diagnostic technology platform, and took the lead in realizing the industrialization of gene chip technology in China With its influence in thalassemia detection series, metazoa has become the drafting unit of relevant national standards and established the first national reference plate for genetic diseases in China In addition to the above-mentioned medical diagnosis business, Fosun is also looking for high-quality targets in the field of in vitro diagnosis in the international market In 2012, he participated in SD biosensor, a Korean listed company (currently holding 18.77%), and became an agent of SD biosensor in China, adding technology platforms such as rapid diagnosis In 2013, the company invested nearly US $22.5 million in Saladax biomedical in the United States, becoming its single largest shareholder (currently holding 24.74%), owning the distribution right and product manufacturing right of the company in China, and improving the layout of the company's cancer chemotherapy drug testing products In addition, the company also invested in genefirst in the field of molecular diagnosis of infectious diseases and cancer in the UK, miacom diagnostics in the field of multiple bacterial identification in Germany, and oxfd, a supplier of tuberculosis in vitro diagnosis products and services Although at present, there is no clear information about whether the medical diagnosis based on the platform of sub energy biology will come into the market However, from the current situation that the split sisram is ready to go to the market, it may slow down for a while But it is not hard to see that Fosun Pharmaceutical is not a "point" layout in various fields, but a systematic construction From this perspective, as long as there are appropriate opportunities, Fosun Pharmaceutical will choose to split and list According to the long-term capital operation ability of Fosun Pharmaceutical, once these platforms are put on the market, they will inevitably set off a wave of M & A.